

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

27 February 2024

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(21 pages by email)

Dear Madam

HALF YEAR REPORTS

In accordance with Listing Rule 4.2A, I attach the Company's Appendix 4D and Interim Financial Report for the half year ended 31 December 2023. This Interim Financial Report should be read in conjunction with the Company's 30 June 2023 Annual Report.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn12079

Appendix 4D

Half Year Report

Name of entity

BIOTRON LIMITED

ABN or equivalent company reference Financial year ended ('current period')

60 086 399 144

31 DECEMBER 2023

Results for announcement to the market

Revenues from ordinary activities	N/A	Nil	to	Nil
Loss from ordinary activities after tax attributable to members	Up	66.81%	to	1,323,809
Net loss for the period attributable to members	Up	66.81%	to	1,323,809
Dividends (distributions)	Amount per security	Franked amount per security		
Final dividend	Nil¢	Nil¢		
Interim dividend	Nil¢	Nil¢		
Previous corresponding period				
Final dividend	Nil¢	Nil¢		
Interim dividend	Nil¢	Nil¢		
Record date for determining entitlements to the dividend.	N/A			
Brief explanation of any of the figures reported above and short details of any bonus or cash issue or other item(s) of importance not previously released to the market:				
Please refer to note 5 of the Interim Financial Report regarding material uncertainty.				
NTA backing	Current period	Previous corresponding period		
Net tangible asset backing per ordinary security	0.13 cents	0.66 cents		

BIOTRON LIMITED

A.B.N. 60 086 399 144

**INTERIM FINANCIAL REPORT
FOR THE HALF-YEAR ENDED
31 DECEMBER 2023**

BIOTRON LIMITED

CONTENTS

	Page
Directors' Report	1
Lead Auditor's Independence Declaration	5
Condensed Interim Statement of Profit or Loss and Other Comprehensive Income	6
Condensed Interim Statement of Financial Position	7
Condensed Interim Statement of Cash Flows	8
Condensed Interim Statement of Changes in Equity	9
Notes to the Condensed Interim Financial Statements	10
Directors' Declaration	14
Independent Auditor's Review Report	15
Corporate Directory	17

BIOTRON LIMITED

DIRECTORS' REPORT

The directors are pleased to submit their report together with the interim financial statements of Biotron Limited ('Biotron' or 'the Company') for the half-year ended 31 December 2023 and the auditor's review report thereon.

DIRECTORS

The names and particulars of the directors of the Company at any time during or since the end of the half-year are:

Mr Michael J. Hoy
Independent and Non-Executive Chairman

Mr Hoy has more than 30 years' corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust.

Mr Hoy has been a director since 7 February 2000 and Chairman since 16 March 2000.

Dr Michelle Miller, BSc, MSc, PhD, GCertAppFin (Finsia)
Managing Director

Dr Miller has worked for over 25 years in the bioscience industry, with extensive experience in commercial drug development. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson & Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund.

Dr Miller was appointed as Managing Director on 21 June 2002.

Dr Susan M. Pond AM, MD DSc, FTSE FAHMS
Independent and Non-Executive Director

Dr Pond has a strong scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, most recently as chairman and managing director of Johnson & Johnson Research Pty Limited (2003 - 2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia.

Dr Pond is currently director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd and the Australian Phenomics Network. She is a member of the Council of the Queensland University of Technology and a Fellow of the Australian Institute of Company Directors, the Academy of Technological Sciences & Engineering, the Academy of Health and Medical Sciences and the Royal Society of NSW.

Dr Pond holds a first-class honours degree in Bachelor of Medicine and Surgery from the University of Sydney and a Doctor of Medicine degree from the University of New South Wales. She obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology and held academic appointments at the University of California San Francisco and the University of Queensland before joining industry.

Dr Pond was appointed as a director on 7 March 2012.

Mr Robert B. Thomas BEc, MSDIA, SF Fin, FICD, FRSN
Independent and Non-Executive Director

Mr Thomas has over 35 years' experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup.

He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.

Mr Thomas has a Bachelor of Economics degree from Monash University (1963 - 1966). He has been a member of the Securities Institute of Australia since 1976 and was appointed as a Fellow to the Institute in 1997. He is a Master Stockbroker and is a Fellow of the Institute of Company Directors.

Mr Thomas was appointed as a director on 7 March 2012.

BIOTRON LIMITED
DIRECTORS' REPORT

Prof Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)
Independent and Non-Executive Director

Professor Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). His current major research interests include viral hepatitis, hepatitis vaccines and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures.

Curative treatments for Hepatitis B infections with antiviral agents represent the current focus for Professor Locarnini who is also interested in intellectual property issues when applied to clinical and diagnostic virology. He is a named inventor on over 20 internationally granted patents.

He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998.

Professor Locarnini is the recipient of numerous awards including the European Association for the Study of Liver Disease (EASL) International Recognition Award in 2010, the Malaysian Liver Foundation's Medal for work on Viral Hepatitis in 2003 and the Gastroenterological Society of Australia (GESA) Distinguished Research Prize in 2013. In 2019 he received the William H. Prusoff HEP DART Lifetime Achievement Award. He is author of 289 peer-reviewed articles, 24 invited editorials and 100 book chapters and reviews and every year delivers numerous invited, plenary, and named lectures at major international meetings and conferences.

Professor Locarnini currently has an academic appointment at the University of Melbourne.

He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic Hepatitis B.

Professor Locarnini was appointed as a director on 23 October 2018.

Mr Peter J. Nightingale
Company Secretary

Mr Nightingale graduated with a Bachelor of Economics degree from the University of Sydney and is a member of the Chartered Accountants Australia and New Zealand. He has worked as a chartered accountant in both Australia and the USA.

As a director or company secretary Mr Nightingale has, for more than 35 years, been responsible for the financial control, administration, secretarial and in-house legal functions of a number of private and public listed companies in Australia and the USA including Bolnisi Gold N.L. and Nickel Industries Limited.

Mr Nightingale is currently a director of ASX listed companies Alpha HPA Limited and Prospech Limited and director of unlisted company Fulcrum Lithium Ltd.

Mr Nightingale has been the Company Secretary since 23 February 1999.

BIOTRON LIMITED

DIRECTORS' REPORT

REVIEW OF OPERATIONS

During the half year under review Biotron Limited ('Biotron' or 'the Company') has achieved key outcomes including:

- Continued detailed post-clinical phase analyses of samples collected during the completed Phase trial of BIT225 for treatment of adults with COVID-19 (BIT225-012).
- Continued detailed post-clinical phase analyses of samples collected during the two completed Phase 2 trials of BIT225 for treatment of HIV-1 infection (BIT225-010 and BIT225-011).
- Continued post-clinical phase activities for all three Phase 2 trials including site monitoring and close-out, and finalising statistical analyses plans ahead of locking of trial databases and unblinding of data.
- Continued the design, synthesis and testing of new compounds with the aim of identifying next-generation lead anti-HIV-1 and anti-SARS-CoV-2 drugs and a lead candidate for HBV.
- Raising \$19,836 in capital from the exercise of Company options.

SARS-CoV-2/COVID-19 and HIV-1 Clinical Programs

During the half year period under review ending 31 December 2023 the Company completed a Phase 2 clinical trial (BIT225-012) with its lead antiviral drug BIT225 for treatment of COVID-19 at sites in Thailand.

The trial commenced in May 2023, and was very quickly fully enrolled with dosing completed in August.

Since completing the clinical phase of the trials the Company has been focused on post-trial activities that are essential parts of the clinical assessment of new drugs. There is a major workload associated with monitoring of all aspects of the completed trial to ensure that all information within patient master files, and subsequently in trial databases, is correct and compliant with international regulatory guidelines.

The double blind, placebo-controlled trial aims to determine if 7 days of treatment with BIT225 commenced within 3 days of onset of COVID-19 symptoms results in reduction in SARS-CoV-2 blood viral load, clinically favourable changes in viral, inflammatory and immune activation markers, as well as improvement in clinical symptoms of COVID-19.

Despite the availability of SARS-CoV-2 vaccines, there remains a need for oral drugs to treat the infection and prevent severe disease, especially in at-risk individuals. BIT225 has an established human safety profile and the potential to be an important first in class drug for COVID-19 treatment.

During the half year post-trial activities have also continued for the two HIV-1 Phase 2 clinical trials (BIT225-010 and -011). These important trials have been designed to generate data that extend the positive findings from previous clinical trials conducted by Biotron in which BIT225 was shown to have positive effects on key immunologic markers of improved health outcomes. The data will be central to demonstrating to potential pharmaceutical partners and regulatory authorities the safety and efficacy of BIT225 in patients with currently unmet medical needs.

End of trial activities for all three clinical trials are primarily in the hands of external Contract Research Organisations (CROs) that are responsible for independent management and oversight of all data generated throughout clinical trials. Once all post-trial activities are completed, the trial database will be locked, the data unblinded and statistical analyses of the data can be completed.

As outlined in a market update on 14 December 2023 external factors beyond the Company's control that have impacted on timelines of data release. Firstly, the workload associated with completing three very complex, data-heavy Phase 2 trials. Secondly, the quantity of data that has been generated from trials involving up to 6 months of treatment plus several weeks follow-up post-dosing. And thirdly, in the aftermath of the COVID-19 pandemic, which caused significant delays across all aspects of clinical studies undertaken globally, many clinical studies in Australia are now in the same post-clinical stage and this is creating backlogs and delays with the CROs involved in the studies. The Company continues to work closely with the CROs involved with the trials to facilitate completion of all essential post-trial activities. Release of headline results is expected in coming weeks.

BIOTRON LIMITED
DIRECTORS' REPORT

Hepatitis B Program

While the clinical programs for HIV-1 and COVID-19 continue to be the Company's main focus, its the Hepatitis B virus (HBV) program continues to be an important preclinical program.

Biotron is working with other experienced groups to access key antiviral HBV assays and continues to make good progress. The aim is to identify a lead series to progress to preliminary safety studies and assessment in animal models of HBV infection.

The current pandemic highlights the importance of novel approaches such as Biotron's viroporin compounds which have the potential to target a broad range of existing and emerging viruses.

Corporate

During the second half of the financial year, the Company will be focused on:

- Completing the post-trial activities and data analyses for the three completed Phase 2 HIV-1 and COVID-19 clinical trials discussed above and reporting results of the trials.
- Identifying next generation lead compounds for HIV-1 and COVID-19 for progression into formal safety studies.
- Identifying a lead compound for HBV, while continuing to characterise the mechanism of action, for progressing into animal model(s) of infection and formal safety studies.
- Sharing data and discussions on the Company's antiviral programs including the HIV-1 and COVID-19 Phase 2 clinical trials with potential pharmaceutical company partners with a view to commercialisation of the Company's antiviral intellectual property.

Subsequent Events

On 8 February 2024, The Company received an R&D Tax Incentive rebate for \$1,645,114 for the financial year ended 30 June 2023.

No other matters or circumstances have arisen since the end of the half-year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

The lead auditor's independence declaration is set out on page 5 and forms part of the Directors' Report for the half-year ended 31 December 2023.

This report has been signed in accordance with a resolution of the directors and is dated 27 February 2024.



Michael J. Hoy
Chairman



Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Biotron Limited

I declare that, to the best of my knowledge and belief, in relation to the review of Biotron Limited for the half-year ended 31 December 2023 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- ii. no contraventions of any applicable code of professional conduct in relation to the review.

KPMG

KPMG

Adam Twemlow
Partner
Brisbane
27 February 2024

BIOTRON LIMITED

**CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2023**

	Notes	31 December 2023 \$	31 December 2022 \$
Continuing Operations			
Other income	6	1,645,114	1,431,283
Administration and consultants' expenses		(295,616)	(456,443)
Depreciation		(21,702)	(22,516)
Direct research and development expenses		(2,198,443)	(1,214,468)
Employee and director expenses		(443,763)	(471,124)
Rent and outgoings expenses		(7,812)	(5,094)
Other expenses from ordinary activities		(49,770)	(79,889)
Operating loss before financing income		(1,371,992)	(818,251)
Interest income	7	48,737	27,283
Interest expense	7	(554)	(2,621)
Net finance (expense)/income		48,183	24,662
Loss before tax		(1,323,809)	(793,589)
Income tax expense		-	-
Loss for the period		(1,323,809)	(793,589)
Other comprehensive income for the period		-	-
Total comprehensive loss for the period		(1,323,809)	(793,589)
Basic and diluted loss per share	8	(0.15) cents	(0.11) cents

The above condensed interim statement of profit or loss and other comprehensive income is to be read in conjunction with the accompanying notes to the condensed interim financial statements.

BIOTRON LIMITED

**CONDENSED INTERIM STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023**

	Notes	31 December 2023 \$	30 June 2023 \$
Current assets			
Cash and cash equivalents		721,684	3,984,387
Other assets	6	1,687,255	46,943
Total current assets		2,408,939	4,031,330
Non-current assets			
Property plant and equipment		31,883	49,890
Other financial assets - bond deposit		54,023	53,930
Total non-current assets		85,906	103,820
Total assets		2,494,845	4,135,150
Current liabilities			
Trade and other payables		193,007	532,396
Employee entitlements		405,106	384,828
Lease liability		28,049	38,582
Total current liabilities		626,162	955,806
Non - current liabilities			
Employee entitlements		-	-
Lease liability		-	6,688
Total non- current liabilities		-	6,688
Total liabilities		626,162	962,494
Net assets		1,868,683	3,172,656
Equity			
Issued capital	11	56,914,683	56,890,392
Reserves	12	1,522,073	1,546,030
Accumulated losses		(56,568,073)	(55,263,766)
Total equity		1,868,683	3,172,656

The above condensed interim statement of financial position is to be read in conjunction with the accompanying notes to the condensed interim financial statements.

BIOTRON LIMITED

**CONDENSED INTERIM STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2023**

	Notes	31 December 2023	31 December 2022
		\$	\$
Cash flows from operating activities			
Cash receipts in the course of operations		-	1,431,283
Payments for research and development		(2,540,171)	(1,286,941)
Cash payments in the course of operations		(769,123)	(993,599)
Interest received		48,206	27,283
Net cash used in operating activities		(3,261,088)	(821,974)
Cash flows from investing activities			
Payments for plant and equipment		-	-
Net cash used in investing activities		-	-
Cash flows from financing activities			
Proceeds from share and option issues		19,836	6,000,000
Transaction costs on share and option issues		-	(427,805)
Lease payments		(21,451)	(19,785)
Net cash from / used in financing activities		(1,615)	5,552,410
Net increase / (decrease) in cash and cash equivalents		(3,262,703)	4,730,436
Cash and cash equivalents at 1 July		3,984,387	1,741,405
Cash and cash equivalents at 31 December		721,684	6,471,841

The above condensed interim statement of cash flows is to be read in conjunction with the accompanying notes to the condensed interim financial statements.

BIOTRON LIMITED

**CONDENSED INTERIM STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2023**

Attributable to equity holders of the Company

	Issued Capital \$	Option Premium Reserve \$	Accumulated Losses \$	Total \$
Balance at 1 July 2022	52,843,994	85,875	(51,837,373)	1,092,496
Total comprehensive income for the period				
Loss for the period	-	-	(793,589)	(793,589)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	-	(793,589)	(793,589)
Contribution by and distribution to owners				
Ordinary shares and options issued	4,700,000	1,300,000	-	6,000,000
Transaction costs on issue of shares and options	(654,333)	-	-	(654,333)
Transfer from reserves to expired options	-	(13,873)	13,873	-
Share based payments	-	226,528	-	226,528
Balance at 31 December 2022	56,889,661	1,598,530	(52,617,089)	5,871,102
Balance at 1 July 2023	56,890,392	1,546,030	(55,263,766)	3,172,656
Total comprehensive income for the period				
Loss for the period	-	-	(1,323,809)	(1,323,809)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the period	-	-	(1,323,809)	(1,323,809)
Contribution by and distribution to owners				
Exercise of options	19,836	-	-	19,836
Transfer from reserve exercise of options	4,455	(4,455)	-	-
Transfer from reserves to expired options	-	(19,502)	19,502	-
Share based payments	-	-	-	-
Balance at 31 December 2023	56,914,683	1,522,073	(56,568,073)	1,868,683

The above condensed interim statement of changes in equity is to be read in conjunction with the accompanying notes to the condensed interim financial statements.

BIOTRON LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2023

1. REPORTING ENTITY

Biotron Limited (the 'Company') is a company domiciled in Australia. The Company is primarily involved in the research and development of new treatments for serious viral diseases such as HIV, HBV, Hepatitis C and coronaviruses.

The annual financial statements of the Company as at and for the year ended 30 June 2023 are available upon request from the Company's registered office at Level 2, 66 Hunter Street, Sydney, NSW, 2000 or at www.biotron.com.au.

2. STATEMENT OF COMPLIANCE

The condensed interim financial statements are general purpose financial statements prepared in accordance with AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

Selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the last annual financial statements as at and for the year ended 30 June 2023. The condensed interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the annual financial statements of the Company as at and for the year ended 30 June 2023 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and the ASX Listing Rules.

These condensed interim financial statements were authorised for issue by the directors on 27 February 2024.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these condensed interim financial statements are the same as those applied in the financial statements as at and for the year ended 30 June 2023.

4. ESTIMATES

The preparation of the condensed interim financial statements requires management to make judgements, estimates, and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expenses. Actual results may differ from these estimates.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were described in the following notes:

- Going Concern (Note 5)

5. GOING CONCERN

The condensed interim financial statements have been prepared on a going concern basis which contemplates the realisation of assets and settlement of liabilities in the ordinary course of business.

The Company has incurred a trading loss of \$1,323,809 in the half-year ended 31 December 2023 and has accumulated losses of \$56,568,073 as at 31 December 2023. The Company has cash on hand of \$721,684 at 31 December 2023 and used net cash of \$3,261,088 in operations for the half-year ended 31 December 2023. As at 31 December 2023, the Company had net assets of \$1,868,683. During the half-year ended 31 December 2023, the Company raised \$19,836 from the conversion of options. These conditions give rise to a material uncertainty that may cast significant doubt upon the Company's ability to continue as a going concern.

The ongoing operation of the Company is dependent on:

- the Company raising additional funding from shareholders or other parties; and
- the Company reducing expenditure in line with available funding.

The directors have prepared cash flow projections that support the ability of the Company to continue as a going concern for the period 1 January 2024 to 31 March 2025. These cash flow projections include significant ongoing expenditure on research and development activities and assume the Company obtains the research and development ('R&D') rebates from the Australian Government, conducts a capital raise and maintains expenditure in line with available funding.

In the event that the Company does not obtain additional funding and reduce expenditure in line with available funding, the achievement of which is significantly uncertain until secured or realised, it may not be able to continue its operations as a going concern and therefore may not be able to realise its assets and extinguish its liabilities in the ordinary course of operations and at the amounts stated in the interim financial statements.

BIOTRON LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2023

	31 December 2023	31 December 2022
	\$	\$
6. OTHER INCOME		
Research and development rebate	1,645,114	1,430,725
Other income	-	558
	1,645,114	1,431,283

The Company prepared and lodged its R&D tax incentive rebate claim for the year ended 30 June 2023 and post half year end received the payment of \$1,645,114. At 31 December 2023 the Company recorded a receivable of \$1,645,114 in relation to the R&D tax incentive rebate.

7. LOSS BEFORE INCOME TAX

The following items are relevant in explaining the financial performance for the half-year:

Interest income on cash deposits	48,737	27,283
Interest expense on lease liability	(554)	(2,621)
Total	48,183	24,662

Lease liability repayment for the six months ended 31 December 2023 was \$21,451 (2022 - \$19,785) and is recognised as cash outflows from lease repayments.

8. LOSS PER SHARE

Basic and diluted loss per share have been calculated using:

Net loss for the period	1,323,809	793,589
	31 December 2023 Number	31 December 2022 Number
Weighted average number of ordinary shares	902,065,199	741,063,148

As the Company is loss making, none of the potentially dilutive options on issue are currently dilutive in the calculation of total earnings per share.

9. RELATED PARTIES

Key management personnel and director transactions

During the half-year ended 31 December 2023, Peter J. Nightingale had a controlling interest in an entity, MIS Corporate Pty Limited, which provided full administrative services, including rental accommodation, administrative staff, services and supplies, to the Company. Fees paid to MIS Corporate Pty Limited during the half-year, which were in the ordinary course of business and on normal terms and conditions, amounted to \$72,000 (31 December 2022 - \$72,000). There were no amounts outstanding at 31 December 2023 and 31 December 2022.

10. SEGMENT REPORTING

The Company operates solely in the biomedical industry in Australia.

BIOTRON LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2023

11. ISSUE CAPITAL

	31 December 2023		30 June 2023	
	Number	\$	Number	\$
Ordinary shares, fully paid at 1 July	901,944,902	56,890,392	701,932,713	52,843,994
<i>Movement in Ordinary Shares:</i>				
Conversion of options 10 October 2023 \$0.06	133,750	8,025	-	-
Conversion of options 26 October 2023 \$0.06	75,902	4,554	-	-
Conversion of options 10 November 2023 \$0.06	114,702	6,882	-	-
Conversion of options 1 December 2023 \$0.06	6,250	375	-	-
Transfer from reserve exercise of options	-	4,455	-	-
Issued ordinary shares 25 November 2022 for \$0.03 ¹	-	-	200,000,000	4,700,000
Conversion of options 25 January 2023 \$0.06	-	-	11,695	702
Conversion of options 22 March 2023 \$0.06	-	-	494	29
Less cost of issue	-	-	-	(654,333)
	902,275,506	56,914,683	901,944,902	56,890,392

¹ In October 2022, the Company offered eligible shareholders to purchase one new share and one listed option for every two shares purchased under a pro-rata renounceable rights issue. Under this offer, the Company issued 140,386,543 ordinary shares and 70,193,272 listed options for cash totaling \$4,211,596. The listed options are each exercisable at \$0.06 to acquire one fully paid ordinary share exercisable at any time up to 25 November 2024.

¹ In November 2022, the Company issued 59,613,457 ordinary shares and 29,806,846 listed options for cash totaling \$1,788,404 under a Share Placement Offer. The listed options are each exercisable at \$0.06 to acquire one fully paid ordinary share exercisable at any time up to 25 November 2024.

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

12. SHARE OPTIONS

During the half year ended 31 December 2023, no options were granted (2022 – 12,000,000). The terms and conditions of the options on issue as follows:

Grant date	Expiry date	Vesting date	Exercise price	Fair value of options granted \$	Options on issue Number	Total Exercised Number	Total Number Expired	Balance at end of the period Number
26 October 2022	25 November 2024	25 November 2022	\$0.06	226,528	12,000,000	-	-	12,000,000

During the half year, 330,604 fully paid ordinary shares (31 December 2022 – nil) were issued through the exercise of 25 November 22 \$0.06 listed options for cash totaling \$19,836. The grant date fair value of the share options transferred from reserves to share capital was \$4,455.

Issue Date	Expiry date	Vesting date	Exercise price	Fair value of options granted \$	Options on issue Number	Total Exercised Number	Total Number Expired	Balance at end of the period Number	Fair value of options at the end of the period \$
25 November 2022	25 November 2024	25 November 2022	\$0.06	1,300,000	100,000,118	342,793	-	99,657,325	1,295,545

BIOTRON LIMITED

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED 31 DECEMBER 2023

The Company has a share option program that entitles key management personnel to be granted options in the Company.

There were no options issued as share base payments to key management personnel during the half-year ended 31 December 2023. The terms and conditions of the options held by key management personnel during the half-year ended 31 December 2023 are as follows:

Grant date	Expiry date	Vesting date	Exercise price	Fair value of options granted \$	Options on issue Number	Total Exercised Number	Total Number Expired	Balance at end of the period Number
26 November 2019	29 November 2023	¹ 26 November 2021	\$0.20	19,502	1,000,000	-	(1,000,000)	-
				19,502	1,000,000	-	(1,000,000)	-

¹ Vesting condition of 1 year service period. To exercise, option holders must remain with the Company or exercise within 2 months of the termination of their employment.

Fair value of options

The fair value of options granted is measured at grant date and recognised as an expense over the period during which the recipients become unconditionally entitled to the options. The fair value of the options granted is measured using an option valuation methodology, taking into account the terms and conditions upon which the options were granted. The amount recognised as an expense is adjusted to reflect the actual number of options that vested during the period.

The fair value of options granted on 26 October 2022 to the lead manager of the rights issue and share placement offers was \$226,528. The Black-Scholes formula model inputs were the Company's share price of \$0.045 at the grant date, a volatility factor of 88.39% based on historic share price performance, a risk-free interest rate of 3.37% based on government bonds, and a dividend yield of 0%.

The fair value of options issued on 24 November 2022 to subscribers of the rights issue and placement offers was \$1,300,000. The fair value of options for the half year ended 31 December 2023 is \$1,295,545. The Black-Scholes formula model inputs were the Company's share price of \$0.037 at the grant date, a volatility factor of 88.39% based on historic share price performance, a risk-free interest rate of 3.37% based on government bonds, and a dividend yield of 0%.

13. SUBSEQUENT EVENTS

On 8 February 2024, The Company received an R&D Tax Incentive rebate for \$1,645,114 for the Financial year ended 30 June 2023.

No other matters or circumstances have arisen since the end of the half-year which significantly affected or may significantly affect the operations of the Company, the results of those operations, or the state of affairs of the Company in future financial years.


BIOTRON LIMITED

DIRECTORS' DECLARATION

In the opinion of the directors of Biotron Limited ("the Company"):

- (a) the condensed interim financial statements and notes, set out on pages 6 to 13, are in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the Company's financial position as at 31 December 2023 and of its performance for the half-year ended on that date; and
 - (ii) complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*; and
- (b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This report has been signed in accordance with a resolution of the directors and is dated 27 February 2024:



Michael J. Hoy
Chairman



Michelle Miller
Managing Director



Independent Auditor's Review Report

To the shareholders of Biotron Limited

Conclusion

We have reviewed the accompanying **Interim Financial Report** of Biotron Limited.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the Interim Financial Report of Biotron Limited does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Company's financial position as at 31 December 2023 and of its performance for the **Interim Period** ended on that date; and
- complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

The **Interim Financial Report** comprises:

- Condensed statement of financial position as at 31 December 2023
- Condensed statement of profit or loss and other comprehensive income, Condensed statement of changes in equity and Condensed statement of cash flows for the Interim Period ended on that date
- Notes 1 to 13 including selected explanatory notes
- The Directors' Declaration.

The **Interim Period** is the 6 months ended on 31 December 2023.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report.

We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with these requirements.

Material uncertainty related to going concern

We draw attention to Note 5, "Going Concern" in the Interim Financial Report. The events or conditions disclosed in Note 5, indicate a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern and, therefore, whether it will realise its assets and discharge its liabilities in the normal course of business, and at the amounts stated in the Interim Financial Report. Our conclusion is not modified in respect of this matter.

KPMG, an Australian partnership and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organisation. Liability limited by a scheme approved under Professional Standards Legislation.

Responsibilities of the Directors for the Interim Financial Report

The Directors of the Company are responsible for:

- the preparation of the Interim Financial Report that gives a true and fair view in accordance with *Australian Accounting Standards* and the *Corporations Act 2001*
- such internal controls as the Directors determine is necessary to enable the preparation of the Interim Financial Report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibilities for the Review of the Interim Financial Report

Our responsibility is to express a conclusion on the Interim Financial Report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the Interim Financial Report does not comply with the *Corporations Act 2001* including giving a true and fair view of the Company's financial position as at 31 December 2023 and its performance for the Interim Period ended on that date, and complying with *Australian Accounting Standard AASB 134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a Interim Period Financial Report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with *Australian Auditing Standards* and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



KPMG



Adam Twemlow
Partner
Brisbane
27 February 2024

BIOTRON LIMITED
CORPORATE DIRECTORY

Directors:

Mr Michael J. Hoy (Chairman).
Dr Michelle Miller (Managing Director).
Dr Susan M. Pond.
Mr Robert B. Thomas.
Prof Stephen Locarnini.

Company Secretary:

Mr Peter J. Nightingale.

Registered Office:

Level 2, 66 Hunter Street
SYDNEY NSW 2000
Phone: 61-2 9300 3344
Fax: 61-2 9221 6333
E-mail: enquiries@biotron.com.au
Homepage: www.biotron.com.au

Share Registrar:

Computershare Investor Services Pty Limited
Level 4, 60 Carrington Street
SYDNEY NSW 2000
Phone: 1300 787 272
Fax: +61 3 9473 2500

Auditors:

KPMG
Level 11, Heritage Lanes
80 Ann Street
BRISBANE QLD 4000

Home Exchange:

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Biotron Limited, incorporated and domiciled in Australia, is a publicly listed company limited by shares.